Business
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A new Series B financing round sees Peter Thiel, co-founder of PayPal and Palantir Technologies, joining entrepreneur Christian Angermayer in investing $35 million in Pittsburgh, Penn.-based biotech Peptilogics.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Surface Oncology has agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of Surface Oncology’s SRF813, a fully human IgG1 antibody and immunotherapy designed to treat cancer.
The company is significantly expanding its footprint with new facilities in the United States and in Europe.
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.